Seminars / Webinars of the CRCI²NA

The seminars / Webinars of the CRCI²NA take place every Thursday at 11:30 am in the Auditorium – IRS UN Building or in remote mode. These seminars are an opportunity to receive renowned scientists and to present their scientific research work, which may lead to new collaborations. Seminars are a great opportunity to promote the scientific expertise of our laboratory.

14 Avril : Webinaire de Dr Didier Jean ,research centre Cordelier : “Molecular heterogeneity in Malignant Pleural Mesothelioma”, Malignant pleural mesothelioma is a thoracic cancer with a realyy poor prognosis and is a major public health concern. The presentation will provide an overview of the molecular alterations and specificities of mesothelioma tumor. A specific focus will highlight the molecular heterogeneity of mesothelioma and give clues on how to take it into account in the perspective of precision medicine for this pathology.
7 Avril : Webinaire de Dr Guillaume Van Niel,Institut Psychiatrie et Neuroscience Paris: “Basic lessons and therapeutic applications of live imaging of extracellular vesicles in vivo”, 

3 Mars : Webinaire de Dr Marc Billaud Co-leader of the “Tumour metabolic targeting” theme in the “Cell death and paediatric cancers” team, director of the Human and Social Sciences Department of the Léon Bernard Centre, member of the Aviesan Cancer ITMO Expert Committee,Lyon Cancer Research Center : “Precision oncology : challenges and promises”, Pression oncology, which classically combines the identification of molecular abnormalities in tumours and the design of drugs targeting the product of these alterations, is often presented as a therapeutic revolution. However, even if this approach has transformed the prognosis of certain cancers, its development and transfer to clinical routine is confronted with numerous epistemological, medical, economic and social obstacles. The question of the challenges and limits of precision oncology will be the subject of this seminar.

February 02 : Webinar by Michael O’Dwyer, ONK Therapeutics : “Rationale for development of an optimized affinity CD38 CAR NK for Multiple Myeloma”

January 25 : Webinar by Dr. Stephanie Torrino, IPMC, Nice : “Post-translational modifications: Key players in cell mechanics” (Cell mechanics is a fundamental determinant of cell and tissue shaping. Dr. Torrino has acquired a solid experience in the study of post-translational modifications (PTM), cellular metabolism and mechanobiology. Since the beginning of her career, she has used and adapted mechanical devices to explore the involvement of mechanical forces on post-translational modification pathways such as ubiquitinylation and SUMOylation. She is now tackling a new challenge by studying the glutamylation pathway (PTM that adds a variable number of glutamate residues as secondary branches of the protein) in cell mechanics. In particular, she showed that matrix rigidification reorganizes glutamine metabolism to promote microtubule glutamylation and force microtubule stabilization, thereby promoting cell mechanics and tumor progression)

January 06 : Webinar by Jean-Baptiste Alberge, post-doctoral fellow at DANA-FARBER Cancer Institute – Boston : “Non-invasive liquid biopsy to characterize circulating tumor cells in precursor and overt multiple myeloma” (Bone marrow (BM) biopsy is the gold standard for diagnosing and monitoring the progression of multiple myeloma (MM), but it is intrusive, painful, and comes with possible secondary complications for patients. Therefore, repeated assessment is not a feasible option for screening and monitoring precursor patients who are asymptomatic. We show the feasibility of characterizing circulating tumor cells (CTCs) from a non-invasive blood biopsy to accompany BM as a method of monitoring disease development. CTCs were detected in 27% of collected patients with monoclonal gammopathy of undetermined significance (MGUS), in 57% of patients with smoldering multiple myeloma (SMM), and correlated with clinical disease measurement, including the International Myeloma Working Group 2/20/20 risk stratification model. Downstream molecular characterization confirms MM-associated genetic alterations and tumor origin of CTCs. Molecular analyses of CTCs were performed in patients with matching bone marrow and clinical fluorescent in situ hybridization (FISH) results. CTCs captured 100% of the BM copy number variation (CNV) events annotated clinically by FISH. In addition, CTC samples identified additional yield, with additional CNVs identified that had not been observed by FISH. In cases that did not have BM biopsy results, sequencing of CTCs revealed the existence of genetic aberrations. Our results demonstrate the clinical correlation and molecular characterization of CTCs from patients with precursor and manifest MM. Our study lays the foundation for non-invasive detection, enumeration, and genomic interrogation of rare peripheral blood CTCs, illustrating the clinical potential of using liquid biopsies for disease monitoring and management in precursor MM).)